Penpulimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | PD-1 |
| Clinical data | |
| Other names | AK105, penpulimab-kcqx |
| MedlinePlus | a625068 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic agent |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| IUPHAR/BPS | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6434H9922N1718O2012S46 |
| Molar mass | 145008.92 g·mol−1 |
Penpulimab is a humanized monoclonal antibody used for the treatment of cancer.[1] It targets the programmed cell death protein 1 (PD-1) receptor.[1][2]
Penpulimab was approved for medical use in China in August 2021,[3] and in the United States in April 2025.[4]
- ^ a b c "Penpulimab-kcqx- penpulimab injection". DailyMed. 24 April 2025. Retrieved 7 July 2025.
- ^ "Penpulimab - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group". AdisInsight. Springer Nature Switzerland AG.
- ^ Cite error: The named reference
Dhillon_2021was invoked but never defined (see the help page). - ^ "FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma". U.S. Food and Drug Administration (FDA). 23 April 2025. Archived from the original on 24 April 2025. Retrieved 24 April 2025. This article incorporates text from this source, which is in the public domain.